nach oben

Endocrine

Erschienen in:

29.07.2019 | Review

Thyroid hormone metabolites and analogues

verfasst von: Rosalba Senese, Federica Cioffi, Giuseppe Petito, Fernando Goglia, Antonia Lanni

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Several metabolic products that derive from l-thyroxine (T4) and 3,3′5-l-triiodothyronine (T3), the main thyroid hormones secreted by the thyroid gland, possess biologic activities. Among these metabolites or derivatives showing physiological actions some have received greater attention: diiodothyronines, iodothyronamines, acetic acid analogues. It is known that increased thyroid hormone (T3 and T4) levels can improve serum lipid profiles and reduce body fat. These positive effects are, however, counterbalanced by adverse effects on the heart, muscle and bone, limiting their use. In addition to the naturally occurring metabolites, thyroid hormone analogues have been developed that either have selective effects on specific tissues or bind selectively to thyroid hormone receptor (TR) isoform. Among these GC-1, KB141, KB2115, and DITPA were deeply investigated and displayed promising therapeutic results in the potential treatment of conditions such as dyslipidemias and obesity. In this review, we summarize the current knowledge of metabolites and analogues of T4 and T3 with reference to their possible clinical application in the treatment of human diseases.

M.A. Kowalik, A. Columbano, A. Perra, Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease. Front Endocrinol. (Lausanne) 9, 382 (2018). https://doi.org/10.3389/fendo.2018.00382 CrossRef

G. Chiellini, J.W. Apriletti, H.A. Yoshihara, J.D. Baxter, R.C. Ribeiro, T.S. Scanlan, A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol. 5(6), 299–306 (1998)CrossRef

S.U. Trost, E. Swanson, B. Gloss, D.B. Wang-Iverson, H. Zhang, T. Volodarsky, G.J. Grover, J.D. Baxter, G. Chiellini, T.S. Scanlan, W.H. Dillmann, The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141(9), 3057–3064 (2000). https://doi.org/10.1210/endo.141.9.7681 CrossRefPubMed

L. Johansson, M. Rudling, T.S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, P. Parini, Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Natl Acad. Sci. USA 102(29), 10297–10302 (2005). https://doi.org/10.1073/pnas.0504379102 CrossRefPubMed

J.Z. Lin, A.J. Martagon, W.A. Hsueh, J.D. Baxter, J.A. Gustafsson, P. Webb, K.J. Phillips, Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 153(12), 6136–6144 (2012). https://doi.org/10.1210/en.2011-2081 CrossRefPubMedPubMedCentral

A. Goncalves, C.C. Tolentino, F.R. Souza, J.C. Huss, L. Zinato Kde, L.T. Lopes, R. Furlanetto Junior, A. Neves Fde, The thyroid hormone receptor beta-selective agonist GC-1 does not affect tolerance to exercise in hypothyroid rats. Arch. Endocrinol. Metab. 59(2), 141–147 (2015). https://doi.org/10.1590/2359-3997000000027 CrossRefPubMed

L. Ye, Y.L. Li, K. Mellstrom, C. Mellin, L.G. Bladh, K. Koehler, N. Garg, A.M. Garcia Collazo, C. Litten, B. Husman, K. Persson, J. Ljunggren, G. Grover, P.G. Sleph, R. George, J. Malm, Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med Chem. 46(9), 1580–1588 (2003). https://doi.org/10.1021/jm021080f CrossRefPubMed

G.J. Grover, K. Mellstrom, L. Ye, J. Malm, Y.L. Li, L.G. Bladh, P.G. Sleph, M.A. Smith, R. George, B. Vennstrom, K. Mookhtiar, R. Horvath, J. Speelman, D. Egan, J.D. Baxter, Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl Acad. Sci. USA 100(17), 10067–10072 (2003). https://doi.org/10.1073/pnas.1633737100 CrossRefPubMed

A. Berkenstam, J. Kristensen, K. Mellstrom, B. Carlsson, J. Malm, S. Rehnmark, N. Garg, C.M. Andersson, M. Rudling, F. Sjoberg, B. Angelin, J.D. Baxter, The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl Acad. Sci. USA 105(2), 663–667 (2008). https://doi.org/10.1073/pnas.0705286104 CrossRefPubMed

10.

D.F. Vatner, D. Weismann, S.A. Beddow, N. Kumashiro, D.M. Erion, X.H. Liao, G.J. Grover, P. Webb, K.J. Phillips, R.E. Weiss, J.S. Bogan, J. Baxter, G.I. Shulman, V.T. Samuel, Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am. J. Physiol. Endocrinol. Metab. 305(1), E89–E100 (2013). https://doi.org/10.1152/ajpendo.00573.2012 CrossRefPubMedPubMedCentral

11.

P.W. Ladenson, J.D. Kristensen, E.C. Ridgway, A.G. Olsson, B. Carlsson, I. Klein, J.D. Baxter, B. Angelin, Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med 362(10), 906–916 (2010). https://doi.org/10.1056/NEJMoa0905633 CrossRefPubMed

12.

Bio, K.: Karo Bio terminates the eprotirome program. (2010). http://www.karobio.com/investormedia/pressreleaser/pressrelease?pid=639535

13.

B. Sjouke, G. Langslet, R. Ceska, S.J. Nicholls, S.E. Nissen, M. Ohlander, P.W. Ladenson, A.G. Olsson, G.K. Hovingh, J.J. Kastelein, Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol. 2(6), 455–463 (2014). https://doi.org/10.1016/S2213-8587(14)70006-3 CrossRefPubMed

14.

R. Taub, E. Chiang, M. Chabot-Blanchet, M.J. Kelly, R.A. Reeves, M.C. Guertin, J.C. Tardif, Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis 230(2), 373–380 (2013). https://doi.org/10.1016/j.atherosclerosis.2013.07.056 CrossRefPubMed

15.

G.D. Pennock, T.E. Raya, J.J. Bahl, S. Goldman, E. Morkin, Cardiac effects of 3,5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J. Pharm. Exp. Ther. 263(1), 163–169 (1992)

16.

S. Goldman, M. McCarren, E. Morkin, P.W. Ladenson, R. Edson, S. Warren, J. Ohm, H. Thai, L. Churby, J. Barnhill, T. O’Brien, I. Anand, A. Warner, B. Hattler, M. Dunlap, J. Erikson, M.C. Shih, P. Lavori, DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 119(24), 3093–3100 (2009). https://doi.org/10.1161/CIRCULATIONAHA.108.834424 CrossRefPubMed

17.

P.W. Ladenson, M. McCarren, E. Morkin, R.G. Edson, M.C. Shih, S.R. Warren, J.G. Barnhill, L. Churby, H. Thai, T. O’Brien, I. Anand, A. Warner, B. Hattler, M. Dunlap, J. Erikson, S. Goldman, Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J. Clin. Endocrinol. Metab. 95(3), 1349–1354 (2010). https://doi.org/10.1210/jc.2009-1209 CrossRefPubMed

18.

C. Di Cosmo, X.H. Liao, A.M. Dumitrescu, R.E. Weiss, S. Refetoff, A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 150(9), 4450–4458 (2009). https://doi.org/10.1210/en.2009-0209 CrossRefPubMedPubMedCentral

19.

A.M. Ferrara, X.H. Liao, H. Ye, R.E. Weiss, A.M. Dumitrescu, S. Refetoff, The thyroid hormone analog DITPA ameliorates metabolic parameters of male mice with Mct8 deficiency. Endocrinology 156(11), 3889–3894 (2015). https://doi.org/10.1210/en.2015-1234 CrossRefPubMedPubMedCentral

20.

C.F. Verge, D. Konrad, M. Cohen, C. Di Cosmo, A.M. Dumitrescu, T. Marcinkowski, S. Hameed, J. Hamilton, R.E. Weiss, S. Refetoff, Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J. Clin. Endocrinol. Metab. 97(12), 4515–4523 (2012). https://doi.org/10.1210/jc.2012-2556 CrossRefPubMedPubMedCentral

21.

M.B. Dratman, On the mechanism of action of thyroxin, an amino acid analog of tyrosine. J. Theor. Biol. 46(1), 255–270 (1974)CrossRef

22.

C.S. Hoefig, T. Wuensch, E. Rijntjes, I. Lehmphul, H. Daniel, U. Schweizer, J. Mittag, J. Kohrle, Biosynthesis of 3-Iodothyronamine from T4 in murine intestinal tissue. Endocrinology 156(11), 4356–4364 (2015). https://doi.org/10.1210/en.2014-1499 CrossRefPubMed

23.

C.S. Hoefig, J. Kohrle, G. Brabant, K. Dixit, B. Yap, C.J. Strasburger, Z. Wu, Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J. Clin. Endocrinol. Metab. 96(6), 1864–1872 (2011). https://doi.org/10.1210/jc.2010-2680 CrossRefPubMed

24.

T.S. Scanlan, K.L. Suchland, M.E. Hart, G. Chiellini, Y. Huang, P.J. Kruzich, S. Frascarelli, D.A. Crossley, J.R. Bunzow, S. Ronca-Testoni, E.T. Lin, D. Hatton, R. Zucchi, D.K. Grandy, 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med 10(6), 638–642 (2004). https://doi.org/10.1038/nm1051 CrossRefPubMed

25.

A. Saba, G. Chiellini, S. Frascarelli, M. Marchini, S. Ghelardoni, A. Raffaelli, M. Tonacchera, P. Vitti, T.S. Scanlan, R. Zucchi, Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151(10), 5063–5073 (2010). https://doi.org/10.1210/en.2010-0491 CrossRefPubMed

26.

V. Mariotti, E. Melissari, C. Iofrida, M. Righi, M. Di Russo, R. Donzelli, A. Saba, S. Frascarelli, G. Chiellini, R. Zucchi, S. Pellegrini, Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern. PLoS ONE 9(11), e106923 (2014). https://doi.org/10.1371/journal.pone.0106923 CrossRefPubMedPubMedCentral

27.

M.E. Manni, G. De Siena, A. Saba, M. Marchini, E. Landucci, E. Gerace, M. Zazzeri, C. Musilli, D. Pellegrini-Giampietro, R. Matucci, R. Zucchi, L. Raimondi, Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. Br. J. Pharm. 168(2), 354–362 (2013). https://doi.org/10.1111/j.1476-5381.2012.02137.x CrossRef

28.

M. Rogowski, L. Gollahon, G. Chellini, F.M. Assadi-Porter, Uptake of 3-iodothyronamine hormone analogs inhibits the growth and viability of cancer cells. FEBS Open Bio 7(4), 587–601 (2017). https://doi.org/10.1002/2211-5463.12205 CrossRefPubMedPubMedCentral

29.

F. Goglia, J. Torresani, P. Bugli, A. Barletta, G. Liverini, In vitro binding of triiodothyronine to rat liver mitochondria. Pflug. Arch. 390(2), 120–124 (1981)CrossRef

30.

C. Horst, H. Rokos, H.J. Seitz, Rapid stimulation of hepatic oxygen consumption by 3,5-di-iodo-L-thyronine. Biochem J. 261(3), 945–950 (1989). https://doi.org/10.1042/bj2610945 CrossRefPubMedPubMedCentral

31.

R. Senese, P. de Lange, G. Petito, M. Moreno, F. Goglia, A. Lanni, 3,5-Diiodothyronine: a novel thyroid hormone metabolite and potent modulator of energy metabolism. Front Endocrinol. (Lausanne) 9, 427 (2018). https://doi.org/10.3389/fendo.2018.00427 CrossRef

32.

R.A. Louzada, D.P. Carvalho, Similarities and differences in the peripheral actions of thyroid hormones and their metabolites. Front Endocrinol. (Lausanne) 9, 394 (2018). https://doi.org/10.3389/fendo.2018.00394 CrossRef

33.

G. Sacripanti, N.M. Nguyen, L. Lorenzini, S. Frascarelli, A. Saba, R. Zucchi, S. Ghelardoni, 3,5-Diiodo-l-thyronine increases glucose consumption in cardiomyoblasts without affecting the contractile performance in rat heart. Front Endocrinol. (Lausanne) 9, 282 (2018). https://doi.org/10.3389/fendo.2018.00282 CrossRef

34.

M. Moreno, A. Lombardi, L. Beneduce, E. Silvestri, G. Pinna, F. Goglia, A. Lanni, Are the effects of T3 on resting metabolic rate in euthyroid rats entirely caused by T3 itself? Endocrinology 143(2), 504–510 (2002). https://doi.org/10.1210/endo.143.2.8613 CrossRefPubMed

35.

I. Lehmphul, G. Brabant, H. Wallaschofski, M. Ruchala, C.J. Strasburger, J. Kohrle, Z. Wu, Detection of 3,5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay. Thyroid 24(9), 1350–1360 (2014). https://doi.org/10.1089/thy.2013.0688 CrossRefPubMed

36.

P.J. Davis, F. Goglia, J.L. Leonard, Nongenomic actions of thyroid hormone. Nat. Rev. Endocrinol. 12(2), 111–121 (2016). https://doi.org/10.1038/nrendo.2015.205 CrossRefPubMed

37.

M. Moreno, A. Giacco, C. Di Munno, F. Goglia, Direct and rapid effects of 3,5-diiodo-L-thyronine (T2). Mol. Cell Endocrinol. 458, 121–126 (2017). https://doi.org/10.1016/j.mce.2017.02.012 CrossRefPubMed

38.

P. Navarrete-Ramirez, M. Luna, R.C. Valverde, A. Orozco, 3,5-di-iodothyronine stimulates tilapia growth through an alternate isoform of thyroid hormone receptor beta1. J. Mol. Endocrinol. 52(1), 1–9 (2014). https://doi.org/10.1530/JME-13-0145 CrossRefPubMed

39.

A. Lanni, M. Moreno, A. Lombardi, F. Goglia, 3,5-Diiodo-L-thyronine and 3,5,3’-triiodo-L-thyronine both improve the cold tolerance of hypothyroid rats, but possibly via different mechanisms. Pflug. Arch. 436(3), 407–414 (1998). https://doi.org/10.1007/s004240050650 CrossRef

40.

A. Lombardi, R. De Matteis, M. Moreno, L. Napolitano, R.A. Busiello, R. Senese, P. de Lange, A. Lanni, F. Goglia, Responses of skeletal muscle lipid metabolism in rat gastrocnemius to hypothyroidism and iodothyronine administration: a putative role for FAT/CD36. Am. J. Physiol. Endocrinol. Metab. 303(10), E1222–E1233 (2012). https://doi.org/10.1152/ajpendo.00037.2012 CrossRefPubMed

41.

E. Silvestri, A. Lombardi, M. Coppola, A. Gentile, F. Cioffi, R. Senese, F. Goglia, A. Lanni, M. Moreno, P. de Lange, Differential effects of 3,5-diiodo-l-thyronine and 3,5,3′-triiodo-l-thyronine on mitochondrial respiratory pathways in liver from hypothyroid rats. Cell Physiol. Biochem 47(6), 2471–2483 (2018). https://doi.org/10.1159/000491620 CrossRefPubMed

42.

A. Lanni, M. Moreno, A. Lombardi, P. de Lange, E. Silvestri, M. Ragni, P. Farina, G.C. Baccari, P. Fallahi, A. Antonelli, F. Goglia, 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J. 19(11), 1552–1554 (2005). https://doi.org/10.1096/fj.05-3977fje CrossRefPubMed

43.

P. de Lange, F. Cioffi, R. Senese, M. Moreno, A. Lombardi, E. Silvestri, R. De Matteis, L. Lionetti, M.P. Mollica, F. Goglia, A. Lanni, Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes 60(11), 2730–2739 (2011). https://doi.org/10.2337/db11-0207 CrossRefPubMedPubMedCentral

44.

E. Silvestri, F. Cioffi, D. Glinni, M. Ceccarelli, A. Lombardi, P. de Lange, A. Chambery, V. Severino, A. Lanni, F. Goglia, M. Moreno, Pathways affected by 3,5-diiodo-l-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry. Mol. Biosyst. 6(11), 2256–2271 (2010). https://doi.org/10.1039/c0mb00040j CrossRefPubMed

45.

M. Moreno, E. Silvestri, R. De Matteis, P. de Lange, A. Lombardi, D. Glinni, R. Senese, F. Cioffi, A.M. Salzano, A. Scaloni, A. Lanni, F. Goglia, 3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. FASEB J. 25(10), 3312–3324 (2011). https://doi.org/10.1096/fj.11-181982 CrossRefPubMed

46.

M.P. Mollica, L. Lionetti, M. Moreno, A. Lombardi, P. De Lange, A. Antonelli, A. Lanni, G. Cavaliere, A. Barletta, F. Goglia, 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. J. Hepatol. 51(2), 363–370 (2009). https://doi.org/10.1016/j.jhep.2009.03.023 CrossRefPubMed

47.

E. Grasselli, A. Voci, I. Demori, G. Vecchione, A.D. Compalati, G. Gallo, F. Goglia, R. De Matteis, E. Silvestri, L. Vergani, Triglyceride Mobilization from lipid droplets sustains the anti-steatotic action of iodothyronines in cultured rat hepatocytes. Front Physiol. 6, 418 (2015). https://doi.org/10.3389/fphys.2015.00418 CrossRefPubMed

48.

E. Grasselli, A. Voci, I. Demori, L. Canesi, R. De Matteis, F. Goglia, A. Lanni, G. Gallo, L. Vergani, 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver. J. Endocrinol. 212(2), 149–158 (2012). https://doi.org/10.1530/JOE-11-0288 CrossRefPubMed

49.

L.F. Iannucci, F. Cioffi, R. Senese, F. Goglia, A. Lanni, P.M. Yen, R.A. Sinha, Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. Sci. Rep. 7(1), 2023 (2017). https://doi.org/10.1038/s41598-017-02205-1 CrossRefPubMedPubMedCentral

50.

P. Fallahi, S.M. Ferrari, E. Santini, S. Camastra, G. Frenzilli, M. Puccini, F. Goglia, A. Lanni, P. Marchetti, A. Antonelli, Both 3,5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. J. Biol. Regul. Homeost. Agents 31(2), 503–508 (2017)PubMed

51.

A. Lombardi, R. Senese, R. De Matteis, R.A. Busiello, F. Cioffi, F. Goglia, A. Lanni, 3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats. PLoS ONE 10(2), e0116498 (2015). https://doi.org/10.1371/journal.pone.0116498 CrossRefPubMedPubMedCentral

52.

R. Senese, F. Cioffi, R. De Matteis, G. Petito, P. de Lange, E. Silvestri, A. Lombardi, M. Moreno, F. Goglia, A. Lanni, 3,5 diiodo-l-thyronine (T(2)) promotes the browning of white adipose tissue in high-fat diet-induced overweight male rats housed at thermoneutrality. Cells 8(3) (2019). https://doi.org/10.3390/cells8030256

53.

S. da Silva Teixeira, C. Filgueira, D.H. Sieglaff, C. Benod, R. Villagomez, L.J. Minze, A. Zhang, P. Webb, M.T. Nunes, 3,5-diiodothyronine (3,5-T2) reduces blood glucose independently of insulin sensitization in obese mice. Acta Physiol. (Oxf.) 220(2), 238–250 (2017). https://doi.org/10.1111/apha.12821 CrossRef

54.

E. Silvestri, R. Senese, F. Cioffi, R. De Matteis, D. Lattanzi, A. Lombardi, A. Giacco, A.M. Salzano, A. Scaloni, M. Ceccarelli, M. Moreno, F. Goglia, A. Lanni, P. de Lange, 3,5-diiodo-l-thyronine exerts metabolically favorable effects on visceral adipose tissue of rats receiving a high-fat diet. Nutrients 11(2) (2019). https://doi.org/10.3390/nu11020278

55.

E. Silvestri, F. Cioffi, R. De Matteis, R. Senese, P. de Lange, M. Coppola, A.M. Salzano, A. Scaloni, M. Ceccarelli, F. Goglia, A. Lanni, M. Moreno, A. Lombardi, 3,5-diiodo-l-thyronine affects structural and metabolic features of skeletal muscle mitochondria in high-fat-diet fed rats producing a co-adaptation to the glycolytic fiber phenotype. Front Physiol. 9, 194 (2018). https://doi.org/10.3389/fphys.2018.00194 CrossRefPubMedPubMedCentral

56.

A. Lombardi, A. Lanni, M. Moreno, M.D. Brand, F. Goglia, Effect of 3,5-di-iodo-L-thyronine on the mitochondrial energy-transduction apparatus. Biochem J. 330(Pt 1), 521–526 (1998). https://doi.org/10.1042/bj3300521 CrossRefPubMedPubMedCentral

57.

A. Cavallo, F. Taurino, F. Damiano, L. Siculella, A.M. Sardanelli, A. Gnoni, Acute administration of 3,5-diiodo-L-thyronine to hypothyroid rats stimulates bioenergetic parameters in liver mitochondria. J. Bioenerg. Biomembr. 48(5), 521–529 (2016). https://doi.org/10.1007/s10863-016-9686-4 CrossRefPubMed

58.

A. Cavallo, A. Gnoni, E. Conte, L. Siculella, F. Zanotti, S. Papa, G.V. Gnoni, 3,5-diiodo-L-thyronine increases FoF1-ATP synthase activity and cardiolipin level in liver mitochondria of hypothyroid rats. J. Bioenerg. Biomembr. 43(4), 349–357 (2011). https://doi.org/10.1007/s10863-011-9366-3 CrossRefPubMed

59.

A. Lombardi, P. de Lange, E. Silvestri, R.A. Busiello, A. Lanni, F. Goglia, M. Moreno, 3,5-Diiodo-L-thyronine rapidly enhances mitochondrial fatty acid oxidation rate and thermogenesis in rat skeletal muscle: AMP-activated protein kinase involvement. Am. J. Physiol. Endocrinol. Metab. 296(3), E497–E502 (2009). https://doi.org/10.1152/ajpendo.90642.2008 CrossRefPubMed

60.

F. Cioffi, R. Senese, G. Petito, P. Lasala, P. de Lange, E. Silvestri, A. Lombardi, M. Moreno, F. Goglia, A. Lanni, Both 3,3′,5-triiodothyronine and 3,5-diodo-L-thyronine are able to repair mitochondrial DNA damage but by different mechanisms. Front Endocrinol. (Lausanne) 10, 216 (2019). https://doi.org/10.3389/fendo.2019.00216 CrossRef

61.

A. Antonelli, P. Fallahi, S.M. Ferrari, A. Di Domenicantonio, M. Moreno, A. Lanni, F. Goglia, 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J. Biol. Regul. Homeost. Agents 25(4), 655–660 (2011)PubMed

62.

W.J. Wood, T. Geraci, A. Nilsen, A.E. DeBarber, T.S. Scanlan, Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo. Chembiochem 10(2), 361–365 (2009). https://doi.org/10.1002/cbic.200800607 CrossRefPubMedPubMedCentral

63.

S. Groeneweg, R.P. Peeters, T.J. Visser, W.E. Visser, Triiodothyroacetic acid in health and disease. J. Endocrinol. 234(2), R99–R121 (2017). https://doi.org/10.1530/JOE-17-0113 CrossRefPubMed

64.

S.I. Sherman, P.W. Ladenson, Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J. Endocrinol. Invest 15(3), 185–190 (1992). https://doi.org/10.1007/BF03348702 CrossRefPubMed

65.

S.I. Sherman, M.D. Ringel, M.J. Smith, H.A. Kopelen, W.A. Zoghbi, P.W. Ladenson, Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J. Clin. Endocrinol. Metab. 82(7), 2153–2158 (1997). https://doi.org/10.1210/jcem.82.7.4054 CrossRefPubMed

66.

S. Kersseboom, S. Horn, W.E. Visser, J. Chen, E.C. Friesema, C. Vaurs-Barriere, R.P. Peeters, H. Heuer, T.J. Visser, In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency. Mol. Endocrinol. 28(12), 1961–1970 (2014). https://doi.org/10.1210/me.2014-1135 CrossRefPubMedPubMedCentral

67.

J. Delbaere, P. Vancamp, S.L. Van Herck, N.M. Bourgeois, M.J. Green, R.J. Wingate, V.M. Darras, MCT8 deficiency in Purkinje cells disrupts embryonic chicken cerebellar development. J. Endocrinol. 232(2), 259–272 (2017). https://doi.org/10.1530/JOE-16-0323 CrossRefPubMed

68.

D. Zada, A. Tovin, T. Lerer-Goldshtein, L. Appelbaum, Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish. Dis. Model Mech. 9(11), 1339–1348 (2016). https://doi.org/10.1242/dmm.027227 CrossRefPubMedPubMedCentral

69.

J.M. Kunitake, N. Hartman, L.C. Henson, J. Lieberman, D.E. Williams, M. Wong, J.M. Hershman, 3,5,3′-triiodothyroacetic acid therapy for thyroid hormone resistance. J. Clin. Endocrinol. Metab. 69(2), 461–466 (1989). https://doi.org/10.1210/jcem-69-2-461 CrossRefPubMed

70.

D. Harrus, H. Demene, E. Vasquez, A. Boulahtouf, P. Germain, A.C. Figueira, M.L. Privalsky, W. Bourguet, A. le Maire, Pathological interactions between mutant thyroid hormone receptors and corepressors and their modulation by a thyroid hormone analogue with therapeutic potential. Thyroid 28(12), 1708–1722 (2018). https://doi.org/10.1089/thy.2017.0551 CrossRefPubMed

71.

S. Horn, S. Kersseboom, S. Mayerl, J. Muller, C. Groba, M. Trajkovic-Arsic, T. Ackermann, T.J. Visser, H. Heuer, Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8. Endocrinology 154(2), 968–979 (2013). https://doi.org/10.1210/en.2012-1628 CrossRefPubMed

72.

S. Groeneweg, R.P. Peeters, T.J. Visser, W.E. Visser, Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone (RTH) syndromes. Mol. Cell Endocrinol. 458, 82–90 (2017). https://doi.org/10.1016/j.mce.2017.02.029 CrossRefPubMed

73.

Y.T. Chin, Z.R. He, C.L. Chen, H.C. Chu, Y. Ho, P.Y. Su, Y.S.H. Yang, K. Wang, Y.J. Shih, Y.R. Chen, J.Z. Pedersen, S. Incerpi, A.W. Nana, H.Y. Tang, H.Y. Lin, S.A. Mousa, P.J. Davis, J. Whang-Peng, Corrigendum: tetrac and NDAT Induce Anti-proliferation via Integrin alphavbeta3 in Colorectal Cancers With Different K-RAS Status. Front Endocrinol. (Lausanne) 10, 241 (2019). https://doi.org/10.3389/fendo.2019.00241 CrossRef

74.

P.J. Davis, H.Y. Tang, A. Hercbergs, H.Y. Lin, K.A. Keating, S.A. Mousa, Bioactivity of thyroid hormone analogs at cancer cells. Front Endocrinol. (Lausanne) 9, 739 (2018). https://doi.org/10.3389/fendo.2018.00739 CrossRef

75.

G. Medina-Gomez, R.M. Calvo, M.J. Obregon, T3 and Triac inhibit leptin secretion and expression in brown and white rat adipocytes. Biochim Biophys. Acta 1682(1–3), 38–47 (2004). https://doi.org/10.1016/j.bbalip.2004.01.007 CrossRefPubMed

76.

H.C. Ha, J.M. Jang, D. Zhou, H.G. Kim, M.J. Back, I.C. Shin, S.Y. Yun, Y. Piao, J.M. Choi, J.H. Won, D.K. Kim, 3, 5, 3′-Triiodothyroacetic acid (TRIAC) is an anti-inflammatory drug that targets toll-like receptor 2. Arch. Pharm. Res 41(10), 995–1008 (2018). https://doi.org/10.1007/s12272-018-1057-8 CrossRefPubMed

77.

J.L. Leonard, Non-genomic actions of thyroid hormone in brain development. Steroids 73(9–10), 1008–1012 (2008). https://doi.org/10.1016/j.steroids.2007.12.016 CrossRefPubMed

78.

J.T. Domingues, D. Cattani, P.A. Cesconetto, B.A. Nascimento de Almeida, P. Pierozan, K. Dos Santos, G. Razzera, F.R. Mena Barreto Silva, R. Pessoa-Pureur, A. Zamoner, Reverse T3 interacts with alphavbeta3 integrin receptor and restores enzyme activities in the hippocampus of hypothyroid developing rats: Insight on signaling mechanisms. Mol. Cell Endocrinol. 470, 281–294 (2018). https://doi.org/10.1016/j.mce.2017.11.013 CrossRefPubMed

79.

H.Y. Lin, H.Y. Tang, M. Leinung, S.A. Mousa, A. Hercbergs, P.J. Davis, Action of Reverse T3 on Cancer Cells. Endocr Res, 1–5 (2019). https://doi.org/10.1080/07435800.2019.1600536

80.

F. Economidou, E. Douka, M. Tzanela, S. Nanas, A. Kotanidou, Thyroid function during critical illness. Horm. (Athens) 10(2), 117–124 (2011). https://doi.org/10.14310/horm.2002.1301 CrossRef

81.

L. Rastogi, M.M. Godbole, R.A. Sinha, S. Pradhan, Reverse triiodothyronine (rT3) attenuates ischemia-reperfusion injury. Biochem Biophys. Res Commun. 506(3), 597–603 (2018). https://doi.org/10.1016/j.bbrc.2018.10.031 CrossRefPubMed

Titel: Thyroid hormone metabolites and analogues
verfasst von: Rosalba Senese
Federica Cioffi
Giuseppe Petito
Fernando Goglia
Antonia Lanni
Publikationsdatum: 29.07.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02025-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Novel thyroid hormones

Thyroid hormone therapy for hypothyroidism

T4 + T3 combination therapy: any progress?

Thyroid hormone therapy: past, present, and future

Novel uses of thyroid hormones in cardiovascular conditions